Potential cardiotoxicity with the use of DuP-941: a case report.

Abstract

OBJECTIVE:

To describe the clinical and pathological features of a patient with probable cardiotoxicity related to a newer chemotherapeutic agent, DuP-941.

PATIENT AND METHODS:

A 42-year-old woman with metastatic breast carcinoma treated with only DuP-941 developed, and died of, heart failure for which no other explanation was apparent.

RESULTS:

Clinically the patient's heart failure resembled that associated with anthracycline cardiotoxicity, as did the pathological features seen at autopsy.

CONCLUSION:

DuP-941 is a new chemotherapeutic drug that may supplant some uses of the anthracyclines because the former may have less cardiotoxicity. This report suggests that in some cases DuP-941 may have cardiotoxic effects as well.

• Authors: S M Walsh, V M Walley, L Chandra, S D Huan, J P Veinot, L A Higginson
• Journal: The Canadian journal of cardiology (Can J Cardiol) Vol. 11 Issue 5 Pg. 419-22 (May 1995) ISSN: 0828-282X [Print] England
• PMID: 7750038 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anthraquinones
• Antineoplastic Agents
• Pyrazoles
• Pyrazolones
• losoxantrone

Topics

• Adult
• Anthraquinones (adverse effects, therapeutic use)
• Antineoplastic Agents (adverse effects, therapeutic use)
• Bone Neoplasms (drug therapy, secondary)
• Breast Neoplasms (pathology, surgery)
• Fatal Outcome
• Female
• Heart (drug effects)
• Heart Failure (chemically induced, pathology)
• Humans
• Lung Neoplasms (drug therapy, secondary)
• Lymphatic Metastasis
• Mastectomy
• Microscopy, Electron
• Myocardium (ultrastructure)
• Myofibrils (ultrastructure)
• Pyrazoles (adverse effects, therapeutic use)
• Pyrazolones